Engimmune Therapeutics
PrivateLast Round
Seed
May 3, 2022
Total Funding Raised
$16.7M
Company Overview
Engimmune Therapeutics is a biotechnology company that develops targeted, 'off-the-shelf' soluble T-cell receptor (TCR) drugs to treat solid tumour cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engimmune Therapeutics Comparables
Compare Engimmune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stereo Biotherapeutics | 87% | |
| Etcembly | 85% | |
| 3T Biosciences | 83% | |
Engimmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 3, 2022 |
Engimmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Novo Holdings | Seed |
| Pureos Bioventures | Seed |
| BaseLaunch | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 16, 2023
Grew 19% QoQ, from 21 to 25 employees.
- May 3, 2022
$17M round led by Novo Holdings and Pureos Bioventures.
Engimmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Engimmune Therapeutics's valuation, stock price, and market status.